{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:47:21Z","timestamp":1793908041755,"version":"4.8.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018744","name":"FH Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018744","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021515","name":"Sanofi Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021515","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022030","name":"Silence Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022336","name":"Esperion Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020480","name":"CSL Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ahj.2020.10.060","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T21:23:12Z","timestamp":1603488192000},"page":"104-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":118,"special_numbering":"C","title":["Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance"],"prefix":"10.1016","volume":"235","author":[{"given":"StephenJ","family":"Nicholls","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Michael","family":"Lincoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold E","family":"Bays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederick E","family":"Grobbee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John JP","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Libby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M","family":"Moriarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Plutzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Sasiela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn","family":"McCluskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Davey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Wolski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9753","key":"10.1016\/j.ahj.2020.10.060_bb0005","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2020.10.060_bb0010","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol","volume":"2018","author":"Grundy","year":"2018","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ahj.2020.10.060_bb0015","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.001800","article-title":"Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis","volume":"1","author":"Jones","year":"2012","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.ahj.2020.10.060_bb0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.5554","article-title":"Association of a combined measure of adherence and treatment intensity with cardiovascular outcomes in patients with atherosclerosis or other cardiovascular risk factors treated with statins and\/or ezetimibe","volume":"1","author":"Khunti","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.ahj.2020.10.060_bb0025","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jacc.2005.07.006","article-title":"The forgotten majority: unfinished business in cardiovascular risk reduction","volume":"46","author":"Libby","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2020.10.060_bb0030","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.mayocp.2018.01.011","article-title":"Reinitiation of statin therapy after discontinuation: a meta-analysis","volume":"93","author":"Ofori-Asenso","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.ahj.2020.10.060_bb0035","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1007\/s13311-018-0670-z","article-title":"Statin-associated muscle disease: advances in diagnosis and management","volume":"15","author":"Taylor","year":"2018","journal-title":"Neurotherapeutics"},{"issue":"6","key":"10.1016\/j.ahj.2020.10.060_bb0040","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"issue":"15","key":"10.1016\/j.ahj.2020.10.060_bb0045","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 Randomized Clinical Trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2020.10.060_bb0050","doi-asserted-by":"crossref","unstructured":"Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Archives of medical science : AMS 2015;11(1):1\u201323.","DOI":"10.5114\/aoms.2015.49807"},{"issue":"17","key":"10.1016\/j.ahj.2020.10.060_bb0055","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment","volume":"36","author":"Stroes","year":"2015","journal-title":"Aetiology and Management Eur Heart J"},{"issue":"2","key":"10.1016\/j.ahj.2020.10.060_bb0060","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10557-017-6723-4","article-title":"The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability","volume":"31","author":"Rosenson","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"10.1016\/j.ahj.2020.10.060_bb0065","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jacc.2014.10.053","article-title":"Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL","volume":"65","author":"Kohli","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.ahj.2020.10.060_bb0070","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"issue":"9841","key":"10.1016\/j.ahj.2020.10.060_bb0075","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ahj.2020.10.060_bb0080","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","article-title":"Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience","volume":"166","author":"Mampuya","year":"2013","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.ahj.2020.10.060_bb0085","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1345\/aph.1K604","article-title":"Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance","volume":"42","author":"Backes","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.ahj.2020.10.060_bb0090","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jacc.2018.04.040","article-title":"The Role of Nutraceuticals in Statin Intolerant Patients","volume":"72","author":"Banach","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.ahj.2020.10.060_bb0095","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jacc.2017.07.752","article-title":"Optimizing Cholesterol Treatment in Patients With Muscle Complaints","volume":"70","author":"Rosenson","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ahj.2020.10.060_bb0100","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4103\/1947-2714.153919","article-title":"Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin D supplementation","volume":"7","author":"Khayznikov","year":"2015","journal-title":"N Am J Med Sci"},{"key":"10.1016\/j.ahj.2020.10.060_bb0105","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.2147\/DDDT.S223153","article-title":"Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study","volume":"13","author":"Derosa","year":"2019","journal-title":"Drug Des Devel Ther"},{"issue":"25","key":"10.1016\/j.ahj.2020.10.060_bb0110","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ahj.2020.10.060_bb0115","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1194\/jlr.M030528","article-title":"AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism","volume":"54","author":"Pinkosky","year":"2013","journal-title":"J Lipid Res"},{"issue":"7","key":"10.1016\/j.ahj.2020.10.060_bb0120","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1194\/jlr.M400018-JLR200","article-title":"Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome","volume":"45","author":"Cramer","year":"2004","journal-title":"J Lipid Res"},{"issue":"11","key":"10.1016\/j.ahj.2020.10.060_bb0125","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","article-title":"Mendelian randomization study of ACLY and cardiovascular disease","volume":"380","author":"Ference","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ahj.2020.10.060_bb0130","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-Lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"issue":"32","key":"10.1016\/j.ahj.2020.10.060_bb0135","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ahj.2020.10.060_bb0140","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/ATVBAHA.113.302677","article-title":"Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus","volume":"34","author":"Gutierrez","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"18","key":"10.1016\/j.ahj.2020.10.060_bb0145","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom Randomized Clinical Trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ahj.2020.10.060_bb0150","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1194\/jlr.M035212","article-title":"ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK","volume":"54","author":"Filippov","year":"2013","journal-title":"J Lipid Res"},{"issue":"5","key":"10.1016\/j.ahj.2020.10.060_bb0155","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1161\/ATVBAHA.117.310676","article-title":"Bempedoic acid lowers low-density lipoprotein cholesterol and attenuates atherosclerosis in low-density lipoprotein receptor-deficient (LDLR+\/\u2212 and LDLR\u2212\/\u2212) Yucatan miniature pigs","volume":"38","author":"Burke","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.ahj.2020.10.060_bb0160","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/ATVBAHA.116.308963","article-title":"Prevention of diet-induced metabolic dysregulation, inflammation, and atherosclerosis in Ldlr(\u2212\/\u2212) mice by treatment with the ATP-citrate lyase inhibitor bempedoic acid","volume":"37","author":"Samsoondar","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2020.10.060_bb0165","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.ahj.2020.10.060_bb0170","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","volume":"62","author":"Ballantyne","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ahj.2020.10.060_bb0175","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance","volume":"9","author":"Thompson","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10.1016\/j.ahj.2020.10.060_bb0180","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.amjcard.2016.03.043","article-title":"Effect of ETC-1002 on serum low-density lipoprotein cholesterol in hypercholesterolemic patients receiving statin therapy","volume":"117","author":"Ballantyne","year":"2016","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.ahj.2020.10.060_bb0185","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jacl.2019.05.003","article-title":"Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial","volume":"13","author":"Lalwani","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ahj.2020.10.060_bb0190","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2020.10.060_bb0195","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"2047487319864671","author":"Ballantyne","year":"2019","journal-title":"Eur J Prev Cardiol"},{"issue":"11","key":"10.1016\/j.ahj.2020.10.060_bb0200","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ahj.2020.10.060_bb0205","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287032030346X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287032030346X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:58:22Z","timestamp":1762077502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000287032030346X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":41,"alternative-id":["S000287032030346X"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2020.10.060","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2020.10.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}